Official Program

San Antonio Breast Cancer Symposium

2026

Generated on November 19, 2026

This file represents the Symposium program as of the date above. The program may change at any time between this date and the end of the Symposium. Complete titles and author listings for abstracts in the Poster Sessions are available in the Symposium App and on the Program page at sabcs.org.

Tuesday, December 8, 2026

Workshop 3: Fundamentals of Real-World Clinical Trial Design

Moderator: Seth A Wander, Mass General Cancer Center, Boston, MA

Workshop 4: Practical Implementation of Clinical AI Tools

Moderator: Mark Robson, Memorial Sloan Kettering, New York, NY

Future Proofing Careers in Oncology: A New Playbook for New Rules

Moderator: Brenda Ernst, Mayo Clinic, Phoenix, AZ, Abirami Sivapiragasam, Medical University of South Carolina, Charleston, SC
Panelist
Debra Patt, Texas Oncology, Austin, TX

Special Session 1: Integrating Lifestyle Medicine into Breast Cancer Care: Science, Strategy, and Skill

Moderator: Tara Sanft
SS1-01: The Expanding Role of Lifestyle Medicine in Breast Cancer Care: Patients, Providers, and Systems
Amy Comander, Mass General Brigham Cancer Institute, Boston, MA
SS1-02: The Science Behind Lifestyle Change: Mechanistic Pathways in Breast Cancer
Lee Jones, City of Hope, Duarte, CA
SS1-03: Helping Patients Help Themselves: Communication Strategies for Lifestyle Change
Eleonora Teplinsky, Valley Health System
Advocate: Kara Kenan, Going Beyond the Pink, Wilmington, NC

Special Session 2: Harnessing Immunity for Breast Cancer Prevention: Emerging Vaccines

Moderator: Mary Nora Disis, University of Washington/FHCC, Seattle, WA
SS2-01: Alpha Lactalbumin for TNBC Prevention
George Thomas Budd, Cleveland Clinic, Cleveland, OH
SS2-02: BRCA Specific Vaccines
Susan Domchek, Basser Center for BRCA, University of Pennsylvania, Philadelphia, PA
SS2-03: MUC1 Ongoing Trials in DCIS
Olivera J Finn, University of Pittsburgh, Pittsburgh, PA
Advocate: Pat Haugen, Research Advocate, Sioux Falls, SD

Special Session 3: A Global View of Breast Cancer — From Population Risk to Precision Care

Moderator: Carlos Henrique H Barrios, LACOG, Porto Alegre, Brazil
SS3-01: Global and Translational Patterns in Breast Cancer Epidemiology
Valerie McCormack, IARC: International Agency for Research on Cancer, Lyon, France
SS3-02: Breast Cancer Screening Across Health Systems Worldwide
Sally Friedewald
SS3-03: Multiomic Architectures of Breast Tumors Across Populations
Marni McClure, National Cancer Institute, Bethesda, MD
SS3-04: The Global Landscape of Breast Cancer Clinical Trials
Ava Kwong, Department of Surgery, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, Hong Kong
Advocate: Tanja Spanic

Navigating Success: Ambition and Sustainable Career Growth for Women in STEM

CD2-1: Navigating Success
Anne Welsh, Psychologist, Author, Speaker, Cambridge, MA

Special Session 9: Modern weight-loss drugs and breast cancer

Moderator: Jennifer Ligibel, Dana-Farber Cancer Institute, Boston, MA
SS9-01: Beyond Weight Loss: Broader Physiologic Impacts of Modern Obesity Therapies
Stephen D Hursting, University of North Carolina, Chapel Hill, NC
SS9-02: Weight‑Loss Agents in Breast Cancer Prevention: Evidence and Outlook
Saba Shaikh, UT Health San Antonio, San Antonio, TX
SS9-03: Biological and Clinical Impact of GLP1 Agonists in Patients Treated with Immune Checkpoint Inhibitors
Joshua Gruber, Stanford University, Palo Alto, CA
Advocate: Vernal Branch

Workshop 1: Beyond Animal Models: Novel Alternative Methods for Breast Cancer Research

Moderator: Sunil Badve, Emory University School of Medicine, Atlanta, GA
WS1-01: Patient Derived Organoid: Modeling Tumor Heterogeneity and Drug Response
Adrian Lee, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA
WS1-02: Microfluidics and Tumor Microenvironment Modeling: Capturing Complexity in Miniature
Konstantinos Konstantopoulos, Johns Hopkins University, Baltimore, MD
WS1-03: Lab on Chip
Ioannis Zervantonakis
Advocate: Carole L Baas, National Cancer Institute, Southlake, TX

Workshop 2: Artificial Intelligence Based Advances in Pathology 

Moderator: Anne Vincent Salomon, Institut Curie, Paris, France
WS2-01: AI-Based Technology
Francisco Sanchez-Vega, Memorial Sloan Kettering, New York, NY
WS2-02: Breast Cancer Subtype Prediction
Ludmil B Alexandrov, UC San Diego, La Jolla, CA
WS2-03: Biomarkers and Therapy
Lee A.D. Cooper, Northwestern University, Chicago, IL
Advocate: Diana T Chingos, Convergent Sciences Virtual Cancer Center, Los Angeles, CA

Educational Session 1: Biomarker-guided Precision Therapy in Metastatic Breast Cancer 

Moderator: Philippe Bedard, Princess Margaret Cancer Centre, Toronto, ON, Canada
ED1-02: Actionable mutations in HR+/HER2- Disease
Maria Coakley, BC Cancer Vancouver, Vancouver, BC, Canada
ED1-03: HER2-Low to HER2-Ultralow: Redefining HER2-Targeted Therapy
Shanu Modi, Memorial Sloan Kettering Cancer Center, New York, NY
ED1-04: Immune Biomarkers Driving Immunotherapy Selection in Metastatic TNBC
Giampaolo Bianchini, IRCCS San Raffaele Hospital, MIlan, Italy
ED1-05: Biomarkers for the WIN!
Kelly Shanahan, METAvivor Research and Support, South Lake Tahoe, CA

Educational Session 2: New Therapies = New Toxicities

Moderator: Alexandra Thomas, Duke University, Durham, NC
ED2-01: Living with New Toxicities: The Patient Perspective on Modern Breast Cancer Therapy
Ellen Landsberger, MBC Alliance, New York, NY
ED2-02: The PI3K Balancing Act: Expanding Options Without Expanding Toxicity
Heather Moore, Duke Cancer Institute, Durham, NC
ED2-03: Unpacking ADCs: When the Magic Bullet Gets Messy
Gustavo Werutsky, LACOG and Hospital Moinhos de Vento, Porto Alegre, Brazil
ED2-04: An FDA-guided Road Map for Minimizing Toxicity of Cancer Therapy
Laleh Amiri-Kordestani

Educational Session 3: Genetic Risk and Screening

Moderator: Mark Robson, Memorial Sloan Kettering, New York, NY
ED3-01: Polygenic Risk Score Implementation
Siddhartha Yadav, Mayo Clinic, Rochester, MN
ED3-02: Clinical Application of Risk Models
Seema A Khan, Northwestern University Feinberg School of Medicine, Chicago, IL
ED3-03: Screening Based on Risk Stratification
Laura Esserman
Advocate: Bob Riter, Cornell University, Ithaca, NY

Educational Session 4: Interplay Between Organ-specific Metastases and Systemic Immunity

Moderator: Justin M. Balko, Vanderbilt University Medical Center, Nashville, TN
ED4-01: Lymph Node Metastases and Impact on the Systemic Immune Response
Sheeba Irshad, King's College London, London, United Kingdom
ED4-02: Tolerogenesis of the Liver Microenvironment
Pepper Schedin
ED4-03: Novel Models of Organotropism in Breast Cancer
Eran R Andrechek, Michigan State University, East Lansing, MI
Advocate: Kai M Pollard, Johns Hopkins University, Baltimore, MD

Educational Session 5: The Selective Elimination of Surgery Paradigm for Invasive Breast Cancer

Moderator: Lajos Pusztai, Yale School of Medicine, New Haven, CT
ED5-01: Ensuring Safety and Accuracy in Predicting Pathologic Complete Response
Marios Konstantinos Tasoulis, The Royal Marsden Hospital, London, United Kingdom
ED5-02: Eliminating Breast Cancer Surgery in Exceptional Responders to Neoadjuvant Therapy- Pitfalls of Clinical Trials and Future Designs
Henry M Kuerer
ED5-03: Radiotherapy Implications when De-escalating Surgery
Khan Atif J, Memorial Sloan Kettering Cancer Center, New York, NY
Advocate: Michael R. Singer, Bronx Community College, Bronx, NY

Educational Session 6: Targeting the Epigenome in Breast Cancer

Moderator: Funda Meric-Bernstam, UT MD Anderson Cancer Center, Houston, TX
ED6-01: Fasting, the Glucocorticoid Receptor, and Endocrine Response
Irene Caffa, University of Genoa, Genoa, Italy
ED6-02: Aberrant Epigenetics in Therapy Resistance and Tumor Progression
Eneda Toska, Johns Hopkins University School of Medicine, Baltimore, MD
ED6-03: Clinical Trials on Epigenetic Targets
Antonio Giordano, Dana-Farber Cancer Institute, Boston, MA

Rapid Fire 1

Moderator: Namita Chittoria, Huntsman Cancer Institute, Salt Lake City, UT, Hikmat Abdel-Razeq, King Hussein Cancer Center, Amman, Jordan
RF1-1: Zanidatamab as a component of neoadjuvant therapy in HER2+ breast cancer: results from the I-SPY2.2 trial
Anthony D Elias, University of Colorado, Aurora, CO
RF1-2: Event-free survival from the randomized phase 2 neohip trial evaluating neoadjuvant taxane, her2-targeted therapy, +/- pembrolizumab in early-stage her2-positive breast cancer
Heather L McArthur, UTSW, Dallas, TX
RF1-3: Circulating tumor DNA (ctDNA) dynamics and pathological complete response (pCR) in high-risk HER2+ early breast cancer (eBC) treated with neoadjuvant trastuzumab deruxtecan followed by paclitaxel + trastuzumab + pertuzumab (T-DXd-THP) vs dose-dense doxorubicin + cyclophosphamide followed by THP (ddAC-THP): A DESTINY-Breast11 (DB-11) analysis
Shanu Modi, Memorial Sloan Kettering Cancer Center, New York, NY
RF1-4: Optimising the duration of trastuzumab in early-stage HER2-positive breast cancer – an Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) meta-analysis
Robert K Hills, University of Oxford, Oxford, United Kingdom
RF1-5: A randomized trial of trastuzumab deruxtecan and biology-driven selection of neoadjuvant treatment for HER2-positive breast cancer: First analysis of the ARIADNE trial
Theodoros Foukakis, Karolinska Institute, Stockholm, Sweden
RF1-6: Patina (aft-38): palbociclib benefit across key prespecified subgroups in hr+/her2-positive advanced breast cancer – final protocol-specified pfs analysis
Otto Metzger, Dana-Farber Cancer Institute, Boston, MA

Rapid Fire 2

Moderator: Yara Abdou, University of North Carolina at Chapel Hill, Chapel Hill, NC, David Rimm, Yale University School of Medicine, New Haven, CT
RF2-1: Updated Overall Survival (OS) Analysis from the Phase 3 ASCENT-07 Study of Sacituzumab Govitecan in Participants with HR+/HER2- Inoperable, Locally Advanced, or Metastatic Breast Cancer Post Endocrine Therapy
Hope S Rugo, City of Hope Comprehensive Cancer Center, Duarte, CA
RF2-2: Prognostic and predictive value of key immunohistochemistry (IHC) protein biomarker expression levels in the NATALEE trial of adjuvant ribociclib (RIB) and nonsteroidal aromatase inhibitor (NSAI) in hormone receptor-positive/human epidermal growth factor receptor 2−negative early breast cancer (HR+/HER2− EBC)
Michael Press, USC, Los Angeles, CA
RF2-3: h&E-derived gene-expression multimodal multitask modeling predicts chemotherapy benefit, distant recurrence risk, and 21-gene recurrence score in tailorx
Joseph Sparano, Icahn School of Medicine at Mount Sinai, New York, CA
RF2-4: Genomic Response-Guided Chemotherapy Omission After Neoadjuvant Ribociclib and Endocrine Therapy in High-Risk HR+/HER2− Early Breast Cancer: Updated Results from the Phase II SOLTI-UNICANCER RIBOLARIS Trial
Milana Arantza Bergamino Sirvén, Hospital Clinic de Barcelona// SOLTI// IDIBAPS, Barcelona, Spain
RF2-5: Prospective Validation of Modified PEPI Following Neoadjuvant (Neoadj) Anastrozole (ANA): Five-Year (5y) Recurrence-free Survival (RFS) from Alliance A011106 (ALTERNATE)
Cynthia X Ma, Washington University in St. Louis, Saint Louis, MO
RF2-6: Cdk2 mediates RB-independent entry into S phase and is a therapeutic target in ER+/RB-deficient, CDK4/6 inhibitor-resistant breast cancer
Chang-Ching A Lin, UT Southwestern Medical Center, Dallas, TX
RF2-7: Results from KEYNOTE-B49: a phase 3, randomized, double-blind study of pembrolizumab (vs placebo) plus chemotherapy in participants with HR+/HER2− locally recurrent inoperable or metastatic breast cancer
Peter Schmid, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom

Wednesday, December 9, 2026

Poster Spotlight 1: Spatial and Immune Drivers of Therapeutic Response in Breast Cancer 

Moderator: Ratna K. Vadlamudi, UT Health San Antonio, SAN ANTONIO, TX
PS1-1: Radiotherapy Initiates an In Situ Vaccination Program Through Sentinel Lymph Node Immune Priming Resulting in Tumor-SLN TCR Clonal Coupling in Early Breast Cancer
Julia Tchou, University of Pennsylvania, Philadelphia, PA
PS1-2: Phase Ib Randomized Trialof aMUC1 Peptide Vaccine as an Immune Interception Strategy in Ductal Carcinoma In Situ: Interim Immune Correlative Studies
Emilia J Diego, University of Pittsburgh School of Medicine and UPMC Hillman Cancer Center, Pittsburgh, PA
PS1-3: Integrated proteomic and spatial transcriptomic profiling reveals biomarkers of response to neoadjuvant chemo-immunotherapy in patients with early-stage triple-negative breast cancer
Ioannis Zerdes, Karolinska Comprehensive Cancer Center and University Hospital & Karolinska institute, Stockholm, Sweden
PS1-4: Gene Expression Signatures in Triple‑Negative Breast Cancer (TNBC) Patients with Early Recurrence Metastases: An Exploratory Cohort Analysis
Sibylle Loibl, GBG Forschungs GmbH; Goethe University and University Medical Center Frankfurt/Main, Neu-Isenburg and Frankfurt/Main, Germany
PS1-5: Spatial multiomic analyses of clinical responders with advanced triple negative breast cancer to intratumoral IL-12 therapy.
Ryan Humphrey, Duke University, Durham, NC
PS1-6: Immune Priming and Response Biomarkers in Breast Cancer
Sangeetha M Reddy, University of Texas Southwestern Medical Center, Dallas, TX
PS1-7: Spatially coordinated extrafollicular DN2/3 B cell niches mark response to neoadjuvant therapy in early triple-negative breast cancer
Sheeba Irshad, King's College London, London, United Kingdom
PS1-8: A CD73+ Neutrophil-Macrophage Spatial Niche Drives Immunotherapy Resistance in Immune-Inflamed Triple-Negative Breast Cancer
Yanhui Wang, Fudan University Shanghai Cancer Center, Shanghai, China
PS1-9: Multimodal profiling reveals distinct ancestry- and environment-associated immune surveillance programmes in breast cancer
Sheeba Irshad, King's College London, London, United Kingdom
PS1-10: Greater distant recurrence-free survival in patients with immune-negative vs. immune-positive TNBC with residual disease after neoadjuvant immunotherapy (IO): a paradox across seven IO arms of the I-SPY2 Trial
Tam Binh Vinh Bui, University of California San Francisco, San Francisco, CA
PS1-11: Psychosocial stressors and cytokine profiles in Black breast cancer survivors
Ji Park, Roswell Park Comprehensive Cancer Center, Buffalo, NY
PS1-12: Spatial Drivers of Response and Resistance in Breast Cancer
Geeta Upadhyay, Uniformed Services University of Health Sciences, Bethesda, MD

Poster Spotlight 2: CNS

Moderator: Andrew Brenner, University of Texas Health Science Center at San Antonio, San Antonio, TX
PS2-1: Exploratory Analysis of CNS-First Relapse in Early Breast Cancer: A Pooled Analysis of the TRIO and GEICAM Trials
Gonzalo D Spera, Translational Research in Oncology, Montevideo, Uruguay
PS2-2: Isolated Central Nervous System (CNS) Recurrence in Metastatic Breast Cancer (mBC): Clinical Features, Treatment Patterns and Outcomes
Angelika M. Starzer, Dana-Farber Cancer Institute, Boston, MA
PS2-3: Surveillance Brain MRIs in Stage IV Breast Cancer: Long Term Results and Biomarker Analysis from a Phase II Trial
Kamran Ahmed, Moffitt Cancer Center, Tampa, FL
PS2-4: Patterns of distant and central nervous system (CNS) recurrences by residual disease (RD) in patients (pts) with triple-negative breast cancer (TNBC) treated with neoadjuvant chemoimmunotherapy: a cohort study
Giacomo De Micheli, European Institute of Oncology, IRCCS, Milan, Italy
PS2-5: Spatial Distribution of Breast Cancer Brain Metastases Predicts Overall Survival Independent of Subtype
Daniel Grange, Memorial Sloan Kettering Cancer Center, New York, NY
PS2-6: Getting Ahead of CNS Metastases — Risk, Patterns of Relapse, and Early Detection
Katarzyna J. Jerzak, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada
PS2-7: Trastuzumab deruxtecan in patients with HER2-low breast cancer and active brain metastases: the TUXEDO-4 phase II trial
Maximilian Marhold, Medical University of Vienna, Vienna, Austria
PS2-8: Datopotamab-deruxtecan (Dato-DXd) in active brain metastases (BM) from triple-negative breast cancer (TNBC): Primary outcome analysis from the TUXEDO-2 trial
Rupert Bartsch, Medical University of Vienna, Vienna, Austria
PS2-9: Alert-based ePRO monitoring improves quality of life and survival in metastatic breast cancer patients with brain metastases: results from the PRO B trial
Elena Laakmann, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
PS2-10: Intracranial activity of sacituzumab govitecan in patients with active brain metastases from HER2-negative breast cancer: results of the multicenter phase II SWOG S2007 trial
Andrew Brenner, University of Texas Health Science Center at San Antonio, San Antonio, TX
PS2-12: Treatment and Outcomes in Established CNS Metastases
Nancy U. Lin, Dana-Farber Cancer Institute, Boston, MA

Poster Spotlight 3: HER2 Positive 

Moderator: Ian Krop
PS3-1: A Phase 1 study of IKS014 (caxmotabart entudotin) in patients with HER2+ solid tumors, and preliminary activity in breast cancer patients previously treated with trastuzumab deruxtecan
Nancy U. Lin, Dana-Farber Cancer Institute, Boston, MA
PS3-2: Disitamab vedotin in HER2-low and -ultralow advanced breast cancer: a prospective, phase 2, two-center clinical trial
Wenjin Yin, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
PS3-3: Efficacy and safety of TQB2102, a bispecific HER2 antibody-drug conjugate, in patients with HER2 immunohistochemistry 0 metastatic breast cancer: a multicenter, single-arm, phase 2 trial
Xiaosong Chen, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
PS3-4: Efficacy and safety of JNJ-95310683 (ARX788), an anti-HER2 antibody drug conjugate (ADC), multiply pre-treated in patients (pts) with HER2+ unresectable or metastatic breast cancer (mBC): primary results of the phase 2 ACE-Breast-03 trial
Adrienne G. Waks, Dana Farber Cancer Institute, Boston, MA
PS3-5: HER2DX ERBB2 mRNA Expression Predicts Clinical Benefit from Trastuzumab Deruxtecan in Advanced Breast Cancer: The HER2-PREDICT (SOLTI-1804) Study)
Tomás Pascual, Clinic Barcelona Comprehensive Cancer Center/Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute/Medicine Department, University of Barcelona/SOLTI Cancer Research Group, Barcelona, Spain
PS3-6: Discussant
Funda Meric-Bernstam, UT MD Anderson Cancer Center, Houston, TX
PS3-7: Clinical efficacy of zongertinib monotherapy in HER2-mutant metastatic breast cancer
David Berz, Valkyrie Clinical Trials, Los Angeles, CA
PS3-8: Zanidatamab + palbociclib (PAL) + fulvestrant (FUL) in patients (pts) with hormone receptor-positive (HR+)/HER2-positive (HER2+) metastatic breast cancer (mBC): Final results and biomarker analyses from a phase 2a trial
Santiago Escrivá-de-Romani, Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, Barcelona, Spain
PS3-9: Zanidatamab (ZW25) combined with tucatinib in patients with HER2-positive metastatic breast cancer (mBC): results from the PRE-ISPY phase Ib trial
Jason Mouabbi, University of Texas MD Anderson Cancer Center, Houston, TX
PS3-10: Phase I Study of Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine and Pepinemab/Trastuzumab in Patients with Metastatic HER2-Positive Breast Cancer (MBC)
Hyo Sook Han, Moffitt Cancer Center, Tampa, FL
PS3-11: Whole-body ABS011 HER2 PET complements tissue biopsy through non-invasive mapping of HER2 heterogeneity: Interim results from the HERMIA study.
Evandro de Azambuja, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B.), Université Libre de Bruxelles (ULB), Bruxelles, Belgium

Poster Spotlight 4: Personalization and De-escalation in Loco Regional Therapy

Moderator: Wendy A Woodward, UT MD Anderson Cancer Center, Houston, TX
PS4-2: Long-term efficacy and biological characterisation of ipsilateral breast tumour recurrences after partial versus whole-breast irradiation: the Florence randomised phase 3 trial
Icro Meattini, University of Florence, Florence, Italy
PS4-4: Acute Toxicity of Ultra-hypofractionated Regional Nodal Irradiation including Internal Mammary Nodes for Breast Cancer (ARROW): A Multicenter Phase 2 Trial
Siyue Zheng, Ruijin Hospital, Shanghai Jiaotong University School Of Medicine, Shanghai, China
PS4-5: More Extensive Locoregional Therapy Does Not Confer Survival Benefit in TNBC
Astrid M Botty van den Bruele, Duke University Hospital, Durham, NC
PS4-6: Updates in Radiotherapy Targets and Regimens
Rachel B Jimenez, Mass General Brigham, Boston, MA
PS4-7: Pathologic Nodal Burden Beyond Current Sentinel Lymph Node Biopsy Omission Criteria in cT1N0M0 Breast Cancer
Ji-Jung Jung, Samsung Medical Center, Seoul, Korea, Republic of
PS4-8: Delayed sentinel lymph node biopsy in patients with ductal carcinoma in situ or low-risk invasive breast cancer: A preplanned interim analysis from the SentiNot 2.0 randomised trial.
Fredrik Wärnberg, Gothenburg University, Gothenburg, Sweden
PS4-9: Nanoparticle-assisted axillary staging enables de-escalation of axillary surgery irrespective of post-neoadjuvant chemotherapy clinical nodal status
Ruixian Chen, West China Hospital, Sichuan University, Chengdu, China
PS4-10: Initial Multicenter Results of the Phase III Randomized CRYSTAL-SIX Trial Comparing Cryoablation With Breast Surgery for Early-Stage Breast Cancer
Vanessa Monteiro Sanvido, Hcor Research Institute, São Paulo, Brazil
PS4-11: Preoperative Endocrine Therapy Tolerance and Two-Year Adjuvant Endocrine Therapy Adherence in Older Women With Early-Stage ER-Positive Breast Cancer: Final Analysis of the POWER Trial
Trish Millard, University of Virginia, Charlottesville, VA
PS4-12: Personalized Descalation
Jai Min Ryu

General Session: Opening Remarks

Moderator: Virginia G Kaklamani, UT Health San Antonio, San Antonio, TX, Carlos L Arteaga, UT Southwestern Medical Center, Dallas, TX

Superconvergence: Artificial Intelligence, Genetics, Biotechnology and the Future of Human Health and Cancer Care 

Moderator: Carlos L Arteaga, UT Southwestern Medical Center, Dallas, TX
GS0-02: Superconvergence: Artificial Intelligence, Genetics, Biotechnology and the Future of Human Health and Cancer Care
Jamie Metzl

General Session 1

Moderator: William M Sikov, Women and Infants Hospital of Rhode Island and Warren Alpert Medical School of Brown University, Providence, RI, Laura M. Spring, Mass General Brigham Cancer Institute, Boston, MA, MA
GS1-1: External Validation of a Causal Multi-Modal AI Model for Prognosis and Chemotherapy Benefit in Node-Negative HR+/HER2- Breast Cancer Patients: Analysis of TAILORx
Nancy Chan, NYU Langone Health, New York, NY
GS1-2: Blinded validation of a causal multi-modal AI model in postmenopausal, node-positive, HR+ breast cancer: analysis of SWOG-8814
Alastair M Thompson, Simon Comprehensive Cancer Center, Indiana University, Indianapolis, IN
GS1-3: Discussant for 1411 and 1420
Frederick M. Howard
GS1-4: Efficacy results of the SWOG-S1418 / NRG Oncology BR006 randomized Phase III trial evaluating adjuvant Pembrolizumab for triple negative breast cancer with residual disease after neoadjuvant chemotherapy.
Lajos Pusztai, Yale School of Medicine, New Haven, CT
GS1-5: Neoadjuvant Famitinib in combine with Camrelizumab and chemotherapy in Triple Negative breast cancer (BCTOP-T-N01): a multicentre, randomized, phase 3 trial
Jun-Jie Li, Fudan University Shanghai Cancer Center, Shanghai, China
GS1-6: Results of phase II NeoTRACT trial: Neoadjuvant tumor infiltrating lymphocyte- and response-adapted chemoimmunotherapy for triple-negative breast cancer (TNBC)
Priyanka Sharma, University of Kansas Medical Center, Westwood, KS
GS1-7: Discussant for 916
Marleen Kok, Netherlands Cancer Institute, Amsterdam, Netherlands
GS1-8: First-line sacituzumab tirumotecan (sac-TMT) vs chemotherapy in unresectable recurrent or metastatic triple-negative breast cancer (TNBC) with PD-L1 CPS <10 or prior early-stage PD-(L)1 exposure: randomized phase 3 OptiTROP-Breast03 trial
Lei Fan, Fudan University Shanghai Cancer Center, Shanghai, China

Clinical Case Discussion

Moderator: William Gradishar, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL
Panelist
Sarah Premji, Sarah Cannon Research Institute, Nashville, TN
Panelist
Meeghan Ann Lautner, University of Wisconsin School of Medicine and Public Health, Madison, WI
Panelist
Melissa P Mitchell, The University of Texas MD Anderson Cancer Center, Houston, TX
Panelist
Sunil Badve, Emory University School of Medicine, Atlanta, GA
Advocate: Michele Rakoff, .Breast Cancer Care and Research Fund, ., CA

Navigating Caregiving Alongside Demanding Careers

CD4-1: Navigating caregiving alongside demanding careers
Anne Welsh, Executive and Leadership Coach, Cambridge, MA

Rising Stars Award Lectures

Moderator: Carlos L Arteaga, UT Southwestern Medical Center, Dallas, TX
AL1-1: Neuronal state plasticity defines opposing neural functions in breast cancer metastasis
Veena Padmanaban, Johns Hopkins University School of Medicine, Baltimore, MD
AL1-2: Treatment-Matched Integration of Patient-Derived Xenografts and Clinical Cohorts Enables Prediction of Differential Chemotherapy Response in Triple-Negative Breast Cancer
Jonathan T. Lei, Baylor College of Medicine, Houston, TX
AL1-3: Impact of environmental hazard burden, somatic genomic profiles, and race on outcomes in metastatic breast cancer
Emily L Podany, Washington University in St. Louis, St. Louis, MO

Poster Session 1

Clinical Controversies: Disrupting the Paradigm in Early Breast Cancer – Small Tumors Big Choices 

Moderator: Kelly K. Hunt, MD Anderson Cancer Center, Houston, TX
CT1-01: Cryoablation: “Freezing the Paradigm: Cryoablation as Definitive Therapy in Early Breast Cancer”
Carissa Calvo-Strube, UT Health San Antonio – Mays Cancer Center, San Antonio, TX
CT1-02: Precision Without Incision: The Role of Stereotactic Breast Radiation
Asal Rahimi, University of Texas Southwestern Medical Center, Dallas, TX
CT1-03: When Less Is More: Endocrine Therapy as Definitive Treatment
Harold J Burstein, Dana-Farber Cancer Institute, Boston, MA
Advocate: Medha Deoras Sutliff, The Ohio State University, Columbus, OH

Special Session 4: Artificial Intelligence in Breast Cancer: From Discovery to Bedside Applications

Moderator: Amrita Basu, University of California San Francisco, San Francisco, CA
SS4-01: Computational Approaches to Precision Oncology: AI-Driven Target Identification
Zhi-Ming Shao, Fudan University Shanghai Cancer Center, Shanghai, China
SS4-02: AI agents for Clinical Decision Support: Real-World Implementation
Sebastian Foersch
SS4-03: Patient Voices: Navigating Care with AI and Large Language Models
Eva A. May, Independent, N/A, NC

State of the Art 1: Treatment Optimization: Genomics and Dynamic Monitoring in Early Breast Cancer  

Moderator: Aleix Prat, Clínic Barcelona Comprehensive Cancer Center, Barcelona, Spain
SA1-01: Genomic Profiling at Diagnosis: Defining Baseline Risk in Early Breast Cancer
Gaia Griguolo, University of Padova, Padova, Italy
SA1-02: Imaging as a Dynamic Biomarker: Assessing Response and Residual Disease
Despina Kontos
SA1-03: Liquid Biopsy and Minimal Residual Disease: Tracking Risk Over Time
Mitchell J Elliott, Yale University, New Haven, CT

Educational Session 10: Stress, Social Determinants, and Breast Cancer: Unpacking Pathways to Risk and Outcomes

Moderator: Sonya A. Reid, Vanderbilt University Medical Center, Nashville, TN
ED10-01: Social Determinants of Health and Stress: Implications for Breast Cancer Outcomes
Chanita Hughes-Halbert
ED10-02: Biology of Stress: Linking Social Stresses to Breast Cancer Outcomes
Samila Obeng-Gyasi, The Ohio State University, Columbus, OH
ED10-03: Multi-Level Stressors and Breast Cancer in Asian American Women: from measurement to interventions
Scarlett Lin Gomez, University of California, San Francisco, San Francisco, CA
Advocate: Tiah Tomlin, Manhattanville University, Purchase, NY

Educational Session 11:The Forgotten Cells of the TME

Moderator: Evanthia Roussos Torres, University of Southern California, Los Angeles, CA
ED11-01: B Cells
Daniel Hollern, The Salk Institute for Biological Studies, La Jolla, CA
ED11-02: NK Cells
Isaac Chan, UT Southwestern, Dallas, TX
ED11-03: Myeloid Cells- Anything but Macrophages
Valentina Hoyos, Baylor College of Medicine, Houston, TX

Educational Session 7: Controversies in Triple Negative Breast Cancer

Moderator: Javier Cortes, IOB Madrid, Institute of Oncology, Hospital Beata María Ana, Madrid, Spain
ED7-01: Neoadjuvant vs. Adjuvant Therapy
Timothy Robinson, University of Bristol, Bristol, United Kingdom
ED7-02: How Small Do You Treat
Carmen Criscitiello, Humanitas University, Milano, Italy
ED7-03: Novel Agents
Rebecca Dent, National University Hospital Singapore, Singapore, Singapore
Advocate: Valencia Robinson, National Breast Cancer Coalition, Washington, DC, FL

Educational Session 8: The Illusion of Precision: Therapies without Molecular Selection for Hormone Receptor Positive Metastatic Breast Cancer 

Moderator: Komal L Jhaveri
ED8-01: Current Landscape with Endocrine-Based Treatment in HR+/HER2- MBC
Kevin Kalinsky, Emory Winship Cancer Institute, Atlanta, GA
ED8-02: Novel CDK Inhibitors
Timothy A. Yap, University of Texas MD Anderson Cancer Center, Houston, TX
ED8-03: Emerging Targeted Approaches in the Treatment of HR Positive MBC
Seth A Wander, Mass General Cancer Center, Boston, MA
ED8-04: Contextualizing Approaches to Meet the Needs of the Patient
Kimberly Parekh, University of Massachusetts, Amherst, MA

Educational Session 9: Targeted Protein Degradation: Novel Approaches and Initial Clinical Steps

Moderator: Qing Zhang, UT Southwestern Medical Center, Dallas, TX
ED9-01: Chemical Approaches to Degraders
Jian Jin, Icahn School of Medicine at Mount Sinai, New York, NY
ED9-02: Biologic Implications of Degraders Compared to Inhibitors
Wang Shaomeng
ED9-03: Lessons from the First PROTAC used in Cancer
Erika Hamilton, Sarah Cannon Research Institute, Nashville, TN

Rapid Fire 3

Moderator: Ana Christina Garrido-Castro, Dana-Farber Cancer Institute, Boston, MA, Alessandra Gennari
RF3-1: Clinical validation of a multimodal model for frontline therapeutic selection in breast cancer
Luca Boscolo-Bielo, Memorial Sloan Kettering Cancer Center, New York, NY
RF3-2: A single cell and spatial atlas of preinvasive breast cancer
Aatish Thennavan, UT MD Anderson Cancer Center, Houston, TX
RF3-3: A Multi-cohort Comparison of Genomic, Clinical, and AI Models for Recurrence Prediction in Early Breast Cancer
Lajos Pusztai, Yale University, New Haven, CT
RF3-4: Validation of Quantitative Standardized High Sensitivity (HS)-HER2 as a prognostic factor for outcomes with trastuzumab deruxtecan (T-DXd) for metastatic breast cancer
Paolo Tarantino, Dana-Farber Cancer Institute, Boston, MA
RF3-5: Pretreatment spatial transcriptomic features associated with response to neoadjuvant HER2-targeted therapy in HER2-positive breast cancer
Emilia Morales, Karolinska Institutet, Stockholm, Sweden
RF3-6: Artera Multimodal AI Digital Pathology Identifies Distant Metastasis and Late Recurrence Risk Beyond the Recurrence Score: External Validation in TAILORx
Rima Patel, Icahn School of Medicine at Mount Sinai, New York, NY
RF3-7: Prospective clinical utility trial of PAM50 intrinsic molecular subtyping to inform physician treatment decisions in metastatic breast cancer- Primary results from HARMONY (TBCRC 072)
Yara Abdou, University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill, NC

Special Session 8: Lobular Breast Cancer: Not a Rare Disease 

Moderator: Christine Desmedt, KU Leuven, Leuven, Belgium
SS8-01: Potential and Challenges of AI for Lobular Breast Cancer Diagnosis and Classification
Fresia Pareja, Memorial Sloan Kettering Cancer Center, New York, NY
SS8-02: Should we use gene expression-based assays for patient with lobular breast cancer?
Christos Sotiriou, Institut Jules Bordet, Brussels, Belgium
SS8-03: Challenges in diagnostic imaging of lobular breast cancer
Caroline Malhaire, Institut Curie, Paris, France
SS8-04: Novel biological insights with clinical relevance
Christine Desmedt, KU Leuven, Leuven, Belgium
Advocate: Claire Turner, Lobular Breast Cancer UK, Manchester, United Kingdom

Poster Session 2

Rapid Fire 4

Moderator: Christos Vaklavas, Shaheenah Dawood
RF4-1: Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy Followed by Adjuvant Pembrolizumab or Placebo for High-Risk, Early-Stage Triple-Negative Breast Cancer (TNBC): Final Analysis Results in the T2N0 Subgroup From the Phase 3 KEYNOTE-522 Study
Peter Schmid, Barts Cancer Institute, Queen Mary University London, London, United Kingdom
RF4-2: Long-term outcomes after pathological complete response (pCR) to neoadjuvant chemo-immunotherapy (NA-CIO) without adjuvant PD-1/PD-L1 inhibition in early-stage triple negative breast cancer: an individual patient pooled analysis
Stephen J Luen, Peter MacCallum Cancer Centre, Melbourne, Australia
RF4-3: Efficacy and safety of bulumtatug fuvedotin (BFv, 9MW2821), a Nectin-4 antibody-drug conjugate (ADC), in patients with advanced triple-negative breast cancer (aTNBC) previously treated with antibody-drug conjugates (ADCs): a phase Ib dose optimization study (9MW2821-CP103).
Nour Abuhadra, Memorial Sloan Kettering Cancer Center, New York, NY
RF4-4: Whole-genome sequencing-defined homologous recombination deficiency predicts carboplatin benefit in early triple-negative breast cancer: long-term survival outcome and biomarker analysis of the phase III PEARLY trial (KCSG BR 15-1)
Joohyuk Sohn, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea, Republic of
RF4-5: Phase II Study of Izalontamab Brengitecan (iza-bren) Combined with Toripalimab in Patients with Unresectable Locally Advanced, Recurrent or Metastatic Triple-Negative Breast Cancer (TNBC)
Jian Zhang, Fudan University Shanghai Cancer Center, Shanghai, China
RF4-6: Safety and preliminary efficacy of SYS6010 monotherapy in patients with HER2-negative, EGFR-expressing breast cancer
Jian Zhang, Fudan University Shanghai Cancer Center, Shanghai, China
RF4-7: Subtyping-guided addition of bevacizumab to treatment of physician’s choice for previously untreated, advanced, basal-like immune-suppressed triple-negative breast cancer: a randomised, multicentre, phase 3 trial
Linxiaoxi Ma, Fudan University Shanghai Cancer Center, Shanghai, China

Thursday, December 10, 2026

Poster Spotlight 13: Triple Negative Breast Cancer

Moderator: Hope S Rugo, City of Hope Comprehensive Cancer Center, Duarte, CA
PS13-1: Phase 1a/1b dose-escalation and -expansion study of BG-C9074 monotherapy in advanced solid tumors: preliminary data from patients with previously treated triple-negative breast cancer (TNBC)
Binghe Xu, Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China
PS13-2: Iparomlimab and tuvonralimab (QL1706)plus nab-paclitaxel , with or without bevacizumab as first-line treatment for recurrent or metastatic triple-negative breast cancer (QUEEN-NATURE): a multicenter, two-arm phase II trial
Hong-Xia Wang, Fudan University Shanghai Cancer Center, shang hai, China
PS13-3: Phase 1 Study of ASTX727 (decitabine and cedazuridine) in combination with paclitaxel and pembrolizumab for pre-treated metastatic triple-negative breast cancer (NCI Protocol #10546)
Roberto A Leon-Ferre, Mayo Clinic, Rochester, MN
PS13-4: Precision DC: Personalized Neoantigen Dendritic Cell Vaccine Pilot Trial for High Risk Triple Negative Breast Cancer after Neoadjuvant Therapy.
Hatem Soliman, Moffitt Cancer Center, Tampa, FL
PS13-5: Initial clinical results from START-002: A Phase 1b/2 study of invikafusp alfa, a first-in-class dual T-cell agonist, in combination with sacituzumab govitecan in triple-negative or HR positive/HER2 negative metastatic breast cancer
Kevin Chin, Marengo Therapeutics, Cambridge, MA
PS13-6: Discussant
Laura A Huppert, University of California San Francisco, San Francisco, CA
PS13-7: Matching-adjusted indirect comparison (MAIC) of sacituzumab govitecan (SG) from ASCENT-03 vs chemotherapy from KEYNOTE-355 in participants with previously untreated advanced triple-negative breast cancer (TNBC)
Adam Brufsky, UPMC Magee-Womens Hospital, Pittsburgh, PA
PS13-8: Matching-adjusted indirect comparison (MAIC) of first-line (1L) sacituzumab govitecan (SG) plus pembrolizumab (pembro) from ASCENT-04/KEYNOTE-D19 vs chemotherapy (chemo) plus pembro from KEYNOTE-355 in participants with PD-L1+ metastatic triple-negative breast cancer (mTNBC)
Clinton Yam, The University of Texas MD Anderson Cancer Center, Houston, TX
PS13-9: Retrospective real-world cohort study of clinical outcomes in patients with recurrent metastatic triple-negative breast cancer (TNBC) who received immunotherapy in the early-stage setting
Tiffany A. Traina, Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY
PS13-10: Immune profile score (IPS) to stratify outcomes in patients with metastatic triple negative breast cancer (mTNBC) treated with immune checkpoint inhibitors (ICIs)
Irene M Kang, City of Hope, Irvine, CA
PS13-11: Sacituzumab Govitecan outcomes according to phenotype changes at metastatic re-biopsy: a real-world analysis of patients with and without an initial triple-negative breast cancer diagnosis
Roberta Caputo, Istituto Nazionale Tumori, IRCCS, “Fondazione G. Pascale", Naples, Italy
PS13-12: A permissive tumor ecosystem primes early immune infiltration during neoadjuvant chemo-immunotherapy in triple-negative breast cancer – longitudinal spatial profiling of response in the NSABP B-59/GBG 96-GeparDouze phase III trial
Marcela Carausu, Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Hôpital Universitaire de Bruxelles, Brussels, Belgium
PS13-13: Discussant
Irene M Kang, City of Hope, Irvine, CA

Poster Spotlight 5: Optimizing and Expanding the Therapeutic Arsenal in HR+ Metastatic Breast Cancer

Moderator: Sarah L Sammons, University of Maryland, Greenebaum Comprehensive Cancer Center, Baltimore, MD, MD
PS5-1: Molecular underpinnings of efficacy and resistance to giredestrant: Rationalizing clinical benefit across breast cancer settings
Ciara Metcalfe, Genentech, South San Francisco, CA
PS5-2: Real-world ctDNA profiling of intrinsic resistance and molecular dynamics to oral SERD monotherapy in HR+/HER2- metastatic breast cancer
Sherry Shen, Memorial Sloan Kettering Cancer Center, New York, NY
PS5-3: Long-term survival outcomes according to <sup>18</sup>F-fluoroestradiol PET/CT uptake in ER-positive/HER2-negative metastatic breast cancer (MBC): updated results from the ET-FES trial
Alessandra Gennari, University of Piemonte Orientale, Novara, Italy
PS5-4: Trastuzumab deruxtecan (T-DXd) versus sacituzumab govitecan (SG) in HER2-low/0 metastatic breast cancer (mBC) by HER2 status and Trop-2 expression
Alexis LeVee, UCLA David Geffen School of Medicine, Los Angeles, CA
PS5-5: Emergence of integrin beta 6 expressing breast cancer persisters through endocrine and CDK4/6 inhibitor therapy.
Justin Rendleman, The Rockefeller University, New York, NY
PS5-6: Discussant: Title TBD
Andrew Davis, Washington University in St. Louis, St. Louis, MO
PS5-7: First-in-human phase 1 dose-escalation and expansion study of MEN2312, an oral and selective dual KAT6A/B inhibitor, as monotherapy and in combination with endocrine therapy (ET) in patients (pts) with ER+/HER2- advanced breast cancer (aBC): preliminary results
Seth Wander, Massachusetts General Hospital, Boston, MA
PS5-8: Pi3kα Inhibitor TOS-358 + fulvestrant +/- CDK4/6i : Safe + Effective combination in P1 HR+HER2- mBC
Antonio Giordano, Dana Farber, Boston, MA
PS5-9: Alisertib + endocrine therapy (ET) in patients (pts) with ET-resistant HR+, HER2- metastatic breast cancer (MBC): evidence of enhanced activity in MYC-activated tumors from the phase 2 ALISCA-Breast1 study
Tufia C. Haddad, Mayo Clinic, Rochester, MN
PS5-10: On-treatment circulating tumor DNA dynamics in evERA Breast Cancer: A Phase III trial of giredestrant + everolimus in patients with estrogen receptor-positive, HER2-negative advanced breast cancer in the post-cyclin-dependent kinase 4/6 inhibitor setting
Adam Brufsky, University of Pittsburgh Cancer Institution, Pittsburgh, PA
PS5-11: Gedatolisib triplet versus giredestrant plus everolimus in HR-positive, HER2-negative advanced breast cancer (aBC): a matching-adjusted indirect comparison (MAIC)
Sara M Tolaney, Dana-Farber Cancer Institute, Boston, MA
PS5-12: Discussant: Title TBD
Rena D. Callahan, University of California, Los Angeles, Los Angeles, CA

Poster Spotlight 6: Are We Listening to Every Patient? Digital Tools, Patient-Reported Outcomes and Dispartities in Breast Cancer

Moderator: Melissa L Bondy, Stanford University School of Medicine, Stanford, CA
PS6-2: Symptom Episodes in CDK4/6 Inhibitor Therapy: Real-World Evidence from Electronic Patient-Reported Outcomes on a Therapy Intelligence Platform
Paul Buzinec, Dosentrx, Plymouth, MN
PS6-3: Online mindfulness intervention for patients receiving chemotherapy for breast cancer: A randomized controlled trial
Fernanda Mesa-Chavez, School of Medicine and Health Sciences, Monterrey, Mexico
PS6-4: An Intervention to Promote Job Retention during (Neo)Adjuvant Chemotherapy: Talking to Employers and Medical Staff about Work (TEAMWork)
Victoria Blinder, Memorial Sloan Kettering Cancer Center, New York, NY
PS6-5: What are Breast Cancer patients Really Talking About? A Natural Language Analysis of Patient Messages Across Clinical and Peer Channels
Neil Margolis, Outcomes4Me, Inc., Boston, MA
PS6-6: Topic 1: There's an App for That: Digital and Mindfulness-Based Support Through Breast Cancer Treatment
Abirami Sivapiragasam, Medical University of South Carolina, Charleston, SC
PS6-7: Balancing prolonged progression and quality of life: palbociclib combination therapy for HR+/HER2-positive advanced breast cancer
Justin Yu, Pfizer Inc, New York, NY
PS6-8: Inhibition of mTOR and disparity in breast cancer survival: secondary analysis of SWOG S1207, a randomized phase 3 clinical trial of adjuvant everolimus in high-risk, hormone receptor-positive, early-stage breast cancer
Kent F. Hoskins, University of Illinois Chicago and University of Illinois Cancer Center, Chicago, IL
PS6-9: Impact of environmental hazard burden, somatic genomic profiles, and race on outcomes in metastatic breast cancer
Emily L Podany, Washington University in St. Louis, St. Louis, MO
PS6-10: Health-related quality of life after 5- versus 15-fraction breast irradiation with simultaneously integrated boost: 2-year results from the randomized phase III YO-HAI5 trial
Renée De Noyette, Ghent University, Ghent, Belgium
PS6-11: Total symptom burden is strongly associated with tolerance of neoadjuvant breast cancer therapy as captured by FACT-GP5
Amrita Basu, University of California San Francisco, San Francisco, CA
PS6-12: Topic 2: Measuring What Matters: Patient-Reported Outcomes and Disparities in Breast Cancer Clinical Trials
Katie E Reeder-Hayes, University of North Carolina at Chapel Hill, Chapel Hill, NC

Poster Spotlight 7: Liquid Biopsy in Motion: From Molecular Residual Disease to Treatment Interception

Moderator: Christos Sotiriou, Institut Jules Bordet, Brussels, Belgium
PS7-1: Global ctDNA kinetics under first-line aromatase inhibitor plus palbociclib: an analysis from PADA-1
François-Clément Bidard, Curie Institute, Paris & Saint-Cloud, France
PS7-2: Impact of timing of ctDNA testing on molecular residual disease detection in early-stage HR+/HER2− Breast Cancer: A DARE Trial Analysis
Lajos Pusztai, Yale School of Medicine, New Haven, CT
PS7-3: Circulating tumor DNA (ctDNA) dynamics during neoadjuvant therapy in early-stage triple-negative breast cancer: preliminary results from the B-STRONGER-I study
Pavani Chalasani, The George Washington Cancer Center, Washington, DC
PS7-5: Circulating tumor DNA dynamics during treatment to predict response and progression in metastatic breast cancer
Andrew A. Davis, Washington University in St. Louis, St. Louis, MO
PS7-6: Molecular surveillance and interception: when should a liquid biopsy change what we do?
Daniel G Stover, Ohio State University Comprehensive Cancer Center, Columbus, OH
PS7-7: Unravelling the genomic evolution of lethal breast cancer using circulating tumour DNA
Nida Pasha, The Institute of Cancer Reasearch, London, United Kingdom
PS7-8: Circulating tumor DNA (ctDNA)-based biomarker analysis of datopotamab deruxtecan (Dato-DXd) versus chemotherapy (CT) in locally recurrent inoperable or metastatic triple-negative breast cancer (mTNBC): a prespecified exploratory analysis of TROPION-Breast02
Tiffany A Traina, Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY
PS7-9: Longitudinal ctDNA tumor fraction captures disease dynamics and survival risk in the TBCRC/AURORA US prospective biospecimen repository in metastatic breast cancer
Adrian Vincent Lee, University of Pittsburgh, Pittsburgh, PA
PS7-10: Serial circulating tumour DNA monitoring in metastatic breast cancer using an ultrasensitive tumour-informed structural variant based assay
Kareena Thakur, Princess Margaret Cancer Centre, Toronto, ON, Canada
PS7-11: Liquid Biopsy-Based Nucleosome Profiling of Cell-Free DNA (cfDNA) to Predict Estrogen Receptor (ER) Status and Response to Endocrine Therapy (ET)
Stefania Morganti, Dana-Farber Cancer Institute, Boston, MA
PS7-12: Early ctDNA dynamics and its association with patient(pt)-reported outcomes (PRO) in <i>ESR1</i>m emergent HR+/HER2− advanced breast cancer (ABC): exploratory analyses from SERENA-6
Stephen Chia, BC Cancer Agency, Vancouver, BC, Canada
PS7-13: Beyond Detection: liquid biopsy for tumor biology, response, and treatment selection
Michail Ignatiadis, Institut Jules Bordet, Brussels, Belgium

Poster Spotlight 8: Novel Insights into Breast Cancer

Moderator: Popi Siziopikou, University of Arizona College of Medicine, Tucson, AZ, Amrita Basu, University of California San Francisco, San Francisco, CA
PS8-1: Does pleomorphic ILC exist? Quantitative digital nuclear morphometry, molecular correlates, and clinical outcomes challenge a long-standing histologic paradigm
Lounes Djerroudi, Memorial Sloan Kettering Cancer Center, New York, NY
PS8-2: Clinicopathologic Correlates of MammaPrint Risk Classification and Comparison with Oncotype DX in Invasive Lobular Carcinoma
Rachael Nakfoor, Cleveland Clinic, Cleveland, OH
PS8-3: Deep learning-based histomorphologic profiling reveals clinically relevant AI-defined breast cancer subgroups, including novel invasive lobular carcinoma phenotypes
Lounes Djerroudi, Memorial Sloan Kettering Cancer Center, New York, NY
PS8-4: Histology-specific performance of genomic and digital pathology risk models in TAILORx
Ngoc-Kim Nguyen, University of Chicago, Chicago, IL
PS8-5: Single-cell subtyping of invasive lobular breast cancer by multicolor immunofluorescence – prognostic impact of proliferative heterogeneity in hormone receptor-negative tumor cells
Sofia Born, Philipps-University Marburg and University Hospital Marburg (UKGM), Marburg, Germany
PS8-6: ILC, a Unique Subtype
Hannah Wen, Memorial Sloan Kettering Cancer Center, New York, NY
PS8-7: Hematoxylin-and-eosin-based AI risk stratification identifies patients with ER+/HER2- early-stage breast cancer who have a favorable treatment outcome on endocrine therapy alone, including those who meet NATALEE-like criteria: independent validation in ABCSG-8
Martin Filipits, Medical University of Vienna, Vienna, Austria
PS8-8: Multi-modal artificial intelligence (AI) predicts neoadjuvant response and long-term outcomes in HER2-positive early breast cancer (HER2+ EBC) treated with chemotherapy de-escalation strategies: analysis of the PHERGain trials.
Giulia Notini, IRCCS San Raffaele Hospital, Milan, Italy, Milano, Italy
PS8-9: Global Breast Cancer Screening Practices: Geographic Variation, Risk-Based Screening Implementation Gaps, and Clinician Perspectives on Artificial Intelligence
Berkay Demirors, University of Pittsburgh, Pittsburgh, PA
PS8-10: Artificial Intelligence (AI)-Based Identification of Invasive Lobular Carcinoma (ILC) Reveals Distinct Treatment and Recurrence Patterns in Two Randomized Breast Cancer Trials
Mishal Ali, University of Chicago, Chicago, IL
PS8-11: A Multimodal Clinical, Genomic, and Digital Pathology Model Improves Risk Stratification and Refines Chemotherapy Benefit Prediction in TAILORx
Ngoc Kim Nguyen, University of Chicago, Chicago, IL

William L. McGuire Award

Moderator: Carlos L Arteaga, UT Southwestern Medical Center, Dallas, TX
PL2-1: Quantitative Biomarkers and Disease Subtypes: The Building Blocks of Precision Medicine
Charles M Perou, University of North Carolina at Chapel Hill, Chapel Hill, NC

General Session 2

Moderator: Richard C Zellars, Alastair M Thompson, Vera Bradley Foundation Breast Cancer Center, IU, Indianapolis, IN
GS2-1: Omission of Breast Surgery in HER2-Positive Primary Breast Cancer Achieving Clinical Complete Response After Anti-HER2-Based Therapy: Primary Results From the AMATERAS-BC Prospective Phase III Trial (JCOG1806)
Tomomi Fujisawa, Gunma Prefectural Cancer Center, Gunma, Japan
GS2-2: Discussant for 979
Henry M Kuerer, UT MD Anderson Cancer Center, Houston, TX
GS2-3: Prospect : post-operative radiotherapy omission in selected patients with early breast cancer trial (ANZ 1002). Final results.
Bruce Mann, The Royal Melbourne Hospital, Parkville, Australia
GS2-4: Neonod2 trial: initial oncologic outcomes following omission of axillary lymph node dissection in breast cancer patients with sentinel lymph node micrometastases after neoadjuvant therapy
Corrado Tinterri, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy
GS2-5: Results of the POSNOC Trial: Omission of Axillary Treatment in Patients Undergoing Breast-Conserving Surgery or Mastectomy with One or Two Sentinel Node Macrometastases
Amit Goyal, Royal Derby Hospital, Derby, United Kingdom

AACR Distinguished Lectureship in Breast Cancer Research

AACR Outstanding Investigator Award for Breast Cancer

Molecular Tumor Board

Moderator: Nicholas Mai, Memorial Sloan Kettering Cancer Center, New York, NY
Panelist
Senthil Damodaran, MD Anderson Cancer Center, Houston, TX
Panelist
Adrienne G. Waks, Dana-Farber Cancer Institute, Boston, MA
Panelist
Fresia Pareja
Panelist
Komal L Jhaveri, Memorial Sloan Kettering Cancer Center, New York, NY
Advocate: Maria Boyce

Poster Session 3

Rapid Fire 8

Moderator: Hope S Rugo, City of Hope Comprehensive Cancer Center, Duarte, CA
RF8-1: Excellent Long Term Outcomes Irrespective of Chemotherapy Use or Age for Clinically High and Genomically UltraLow Risk Early Breast Cancer in the MINDACT trial
Laura van t Veer, University California San Francisco, San Francisco, CA
RF8-2: 2b or not 2b: updated results from the wisdom 1.0 study show continued reduction in locally advanced cancers in the risk-based arm
Laura Esserman, University of California, San Francisco, San Francisco, CA
RF8-3: Loco-regional irradiation in patients with clinical N1 biopsy-proven axillary node involvement at presentation who become pathologically node-negative after neoadjuvant chemotherapy: 8-year outcome results of NRG Oncology/NSABP B-51/RTOG 1304
Eleftherios P Mamounas, AdventHealth Cancer Institute, Orlando, FL
RF8-4: A phase II trial of datopotamab deruxtecan (Dato-DXd) or trastuzumab deruxtecan (T-DXd) in patients with HER2-negative (HER2-low or HER2-0) metastatic breast cancer (mBC) after progression on prior antibody drug conjugate therapy: Primary results from Arm E (Dato-DXd after T-DXd for HR-positive/HER2-negative mBC) of the TRADE-DXd trial (TBCRC 064)
Ana C Garrido-Castro, Dana-Farber Cancer Institute, Boston, MA
RF8-5: Treatment discontinuations and patient-reported outcomes in lidERA Breast Cancer: A Phase III trial of giredestrant in patients with estrogen receptor-positive, HER2-negative early breast cancer
Sara A Hurvitz, Fred Hutchinson Cancer Center, Seattle, WA
RF8-6: Adjuvant giredestrant in combination with abemaciclib in high-risk, estrogen receptor-positive, HER2-negative early breast cancer: Initial results from a substudy of the Phase III lidERA Breast Cancer trial
Rena D. Callahan, UCLA David Geffen School of Medicine, Los Angeles, CA

Special Session 5: Policy, Access and Financial Toxicity: Understanding the Drivers of Disparities

Moderator: Mariana Chavez Mac Gregor, MD Anderson Cancer Center, Houston, TX
SS5-01: Access is the way to High-Quality Breast Cancer Care
Rachel A. Freedman, Dana-Farber Cancer Institute, Boston, MA
SS5-02: Policy Matters: Federal and State Reforms and Their Impact on Breast Cancer Outcomes
Mya L. Roberson, University of North Carolina at Chapel Hill, Chapel Hill, NC
SS5-03: Financial Toxicity in Breast Cancer: The Hidden Burden Beyond Treatment
Fumiko Chino, UT MD Anderson Cancer Center, Houston, TX
SS5-04: The Role of Patient Advocacy: To Improve Access Beyond Borders
Mary Jimenez, Director, Alamo Advocate Program, San Antonio, TX

State of the Art 2: Expanding the Therapeutic Arsenal with Radioligand Therapies in Breast Cancer

Moderator: Alessandra Gennari, University of Piemonte Orientale, Novara, Italy
SA2-01: Learning from the Prostate Cancer Playbook
Daniel George
SA2-02: Radioligands in Breast Cancer: Emerging Targets and Early Clinical Promise Strategies in Breast Cancer
Somali Gavane, Memorial Sloan Kettering Cancer Center, New York, NY
Advocate: Patrica Lloyd Kellerhouse, Thomas Edison State College, Trenton, NJ

Translational Controversies: Utility of MRD and ctDNA in Breast Cancer

Moderator: David Cescon, Princess Margaret Cancer Centre/UHN, Toronto, ON, Canada
CT2-01: Is MRD Ready for Prime Time?
Nick Turner, Royal Marsden, London, United Kingdom
CT2-02: ctDNA Guided Endpoints in Metastatic Disease
Jo Chien, UCSF, San Francisco, CA
CT2-03: Endpoints in Modern Clinical Trials
Yu Shyr, Vanderbilt University School of Medicine, Nashville, TN
CT2-04: Navigating MRD Testing: Partnering with Patients to Optimize Care
Patricia A Spears, University of North Carolina, Chapel Hill, NC

Educational Session 12: ADC Controversies 

Moderator: William Gradishar, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL
ED12-01: Management of Toxicities Associated with ADCs
Peter Schmid, Queen Mary University of London, London, United Kingdom
ED12-02: Sequencing and Biomarker Selection in the use of ADCs
Ana Christina Garrido-Castro, Dana-Farber Cancer Institute, Boston, MA
ED12-03: How do we Optimally Incorporate ADCs in MBC
Giulia Notini, IOB, Hospital Beata María Ana, Madrid, Spain
Advocate: Tammy Uhl

Educational Session 13: The Evolving Role of Neoadjuvant Endocrine Therapy 

Moderator: Erika Hamilton, Sarah Cannon Research Institute, Nashville, TN
ED13-01: Neoadjuvant Endocrine Therapy: What Have We Learned In the Past 20 Years.
Harold Burstein, Dana-Farber Cancer Institute, Boston, MA
ED13-02: Redefining Response: Beyond pCR to Complementary Biologic Endpoints
Cynthia X Ma, Washington University in St. Louis, St. Louis, MO
ED13-03: Neoadjuvant Endocrine Therapy as a Tool for Personalizing Surgical Management
Taiwo Adesoye, University of Texas MD Anderson Cancer Center, Houston, TX
Advocate: Sharon Rivera-Sanchez, N/A, N/A, VA

Educational Session 14: Beyond Age: Practical Approaches to Optimizing Breast Cancer Care in Older Patients

Moderator: Hyman B Muss, UNC-Chapel Hill, Chapel Hill, NC
ED14-2: Defining Vulnerability: Geriatric Assessment as a Tool for Personalized Treatment Planning
Enrique Soto Pérez de Celis, University of Colorado Anschutz, Aurora, CO
ED14-3: Therapeutic Trade‑offs in the Aging Population: Balancing Efficacy, Toxicity, and Competing Risks
Etienne G Brain, Institut Curie, Saint-Cloud, France
ED14-4: Care and Toxicity Mitigation: Strategies to Preserve Function and Improve Outcomes
Meghan Karuturi
ED14-5: A Patient Prospective of Cancer Care in Older Adults
Sandra A Finestone, American Behavorial Studies Institute, Anaheim, CA

Educational Session 15: It Takes a Host: The Tumor Microenvironment Revisited

Moderator: Ines Vaz-Luis, Gustave Roussy, Villejuif, France
ED15-01: Impact of the Circadian Clock on Systemic and Local Immunity
Selma Masri
ED15-02: Thymic Health as Tumor-agnostic Immune Biomarker
Simon Bernatz, Goethe University, Frankfurt am Main, Germany
ED15-03: Obesity-associated Changes in Breast Cancer Biology
Christine Desmedt, KU Leuven, Leuven, Belgium
ED15-04: Hormones in action in pre and postmenopausal patients
Cathrin Brisken
Advocate: Christine Hodgdon, GRASP Cancer, Baltimore, MD

Educational Session 16: Radiotherapy and Emerging Systemic Therapies: Friends or Frenemies?

Moderator: Jonathan Strauss, Feinberg School of Medicine, Chicago, IL
ED16-01: Payload Meets Beam: ADCs and Radiotherapy in Breast Cancer
Mylin A Torres, Emory University, Atlanta, GA
ED16-02: Cutting Edge Combinations or Conflict: RT with CDK4/6 or PARP Inhibitors
Corey W. Speers, University of Alabama-Birmingham Heersink School of Medicine, Birmingham, AL
ED16-03: Enhancement or Hype? Immunotherapy + RT
Rita Nanda, The University of Chicago Medicine, Chicago, IL
Advocate: Judy Perkins

Rapid Fire 5

Moderator: Allison Kurian, Stanford University, Stanford, CA, Kimberley T Lee, University of Pennsylvania, Philadelphia, PA
RF5-1: Can FAST MRI detect breast cancers missed by mammography for women with average mammographic density attending their first screening mammogram? – results of the interim analysis of the DYAMOND Trial
Lyn Isobel Jones, Bristol NHS Foundation Trust, Bristol, United Kingdom
RF5-2: De-escalated Denosumab (Every 12 versus Every 4 Weeks) Maintains Efficacy for Prevention of Symptomatic Skeletal Events in Patients with Bone Metastases: Breast Cancer Stratum from the Randomized Phase-III Non-Inferiority REDUSE Trial (SAKK 96/12)
Andreas Müller, Kantonsspital Winterthur, Winterthur, Switzerland
RF5-3: Pink! Leben: a randomized controlled trial of an acceptance and commitment therapy-based digital intervention for psychological distress in breast cancer patients across treatment phases
Christian Schem, Mammazentrum Hamburg am Krankenhaus Jerusalem, Hamburg, Germany
RF5-4: Quality of life for patients aged 40 or older with oestrogen receptor-positive HER2-negative early breast cancer and 0-9 involved axillary lymph nodes within the OPTIMA trial
Janet Audrey Dunn, University of Warwick, Coventry, United Kingdom
RF5-5: Temperature-controlled hand-foot cooling prevents chemotherapy-induced polyneuropathy (cipn): updated real-world data collection in 600 patients
Athina Kostara, MVZ Medical Center Duesseldorf, Duesseldorf, Germany
RF5-6: The role of estrogen plus progestogen on breast cancer incidence: a systematic review and meta-analysis of randomized clinical trials
Margaret S Pichardo, University of Pennsylvania,, Philadelphia, PA
RF5-7: Social drivers, age-at-onset, and later stage at diagnosis in association with aggressive RNA-based breast cancer subtypes among Black women
Sarah C Van Alsten, University of North Carolina at Chapel Hill, Chapel Hill, NC

State of the Art 3: Innovative Translational Methods: Highlights from the AACR Annual Meeting

Moderator: Charles Perou, Carlos L Arteaga, UT Southwestern Medical Center, Dallas, TX
SA3-01: Deep learning models to predicts breast cancer risk
Regina Barzilay, MIT, Cambridge, MA
SA3-02: Macrophages as Therapeutic Gatekeepers: From Biology to Clinical Application
Jennifer L Guerriero, Mass General Brigham Cancer Institute, Boston, MA
SA3-03: Innate copy number changes informing novel high risk genomic regions
Samuel A.J.R. Aparicio, BC Cancer/UBC, Vancouver, BC, Canada

Poster Session 4

Rapid Fire 6

Moderator: Rohini K. Bhatia, Emory University, Winship Cancer Institute, Atlanta, GA, Roshni Rao, Columbia University Medical Center, New York, NY
RF6-1: Interim event-free survival with peri-operative immune checkpoint inhibition and cryoablation in residual triple-negative breast cancer
Heather L McArthur, UTSW, Dallas, TX
RF6-2: Breast-mri trial: the paradox of preoperative breast mri — more surgery, no detectable survival benefit in a randomized trial
Bruna S Mota, ICESP, Sao Paulo, Brazil
RF6-3: Technical outcomes of node marking and targeted axillary dissection after neoadjuvant chemotherapy in node-positive breast cancer: results from 1295 participants in the ATNEC trial
Amit Goyal, Royal Derby Hospital, Derby, United Kingdom
RF6-4: Prediction of pathological tumor size in 2,138 breast cancer patients treated with breast-conserving surgery: comparative analysis of preoperative imaging modalities in the prospective multicenter MELODY (EUBREAST-4 / iBRA-NET / AGO-B-062) study
Nikolas Tauber, University of Luebeck, Luebeck, Germany
RF6-5: Axillary Radiotherapy as an Alternative to Axillary Lymph Node Dissection in Sentinel Node-Positive Breast CancerPatientsAfter Neoadjuvant Therapy: Three-Year Outcomes from the ADARNAT Pilot Randomized Trial
Amparo Garcia-Tejedor, Bellvitge Hospital, L'Hospitalet de Llobregat, Spain
RF6-6: One-week or three-week Adjuvant Radiation in Breast Cancer (OTHAR) – A Phase III Non-Inferiority Randomized controlled Trial- Early outcomes and Acute Toxicity Results
Supriya Mallick, National Cancer Institute-All India Institute of Medical Sciences,New Delhi, New Delhi, India
RF6-7: Oncological safety of breast-conserving surgery following neo-adjuvant chemotherapy in locally advanced breast cancer: Results from a randomized controlled trial
Ankita Manan Sheth, Tata Memorial Hospital, Mumbai, India

Friday, December 11, 2026

Poster Spotlight 10: Translational Insights into CDK4/6 Inhibitor Resistance and Novel Therapeutic Strategies 

Moderator: Seth A Wander, Mass General Brigham Cancer Institute, Boston, MA
PS10-1: Circulating tumor DNA to inform timing of CDK4/6 inhibitor treatment and to understand treatment failure in estrogen receptor-positive/HER2 negative advanced breast cancer – results from the SONIA trial
John WM Martens, Erasmus MC Cancer institute, Rotterdam, Netherlands
PS10-2: Tumor subtype conversion after first-line endocrine therapy plus CDK4/6 inhibitor progression in patients with Hormone Receptor-positive, HER2-negative advanced breast cancer (HR+/HER2- aBC): results from the multicenter, real-world Italian study PALMARES-2
Leonardo Provenzano, IFOM ETS, AIRC Institute of Molecular Oncology, Milan, Italy
PS10-3: Distinct molecular mechanisms between early and late resistance to palbociclib with endocrine therapy in HR+/HER2− metastatic breast cancer
Hee Kyung Ahn, Samsung Medical Center, Seoul, Korea, Republic of
PS10-4: Ribociclib versus palbociclib in HER2-enriched HR+/HER2− metastatic breast cancer: results from the randomized HARMONIA (SOLTI-2101/AFT-58) phase III trial
Tomás Pascual, Hospital Clínic de Barcelona // August Pi i Sunyer Biomedical Research Institute // SOLTI, Barcelona, Spain
PS10-5: Evolving Translational Approaches to Model 1st Generation CDK4/6 Inhibitor Resistance
Julie Nangia, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX
PS10-6: Phase I/II Trial of INX-315, an oral selective CDK2 inhibitor, in combination with abemaciclib and fulvestrant after progression on a CDK4/6 inhibitor and endocrine therapy in HR+/HER2-negative metastatic breast cancer
Antoinette R Tan, Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, NC
PS10-7: The Wnt pathway is a targetable vulnerability of drug-tolerant persister cells surviving CDK4/6 inhibitor treatment
Yuki Matsunaga, UT Southwestern Medical Center, Dallas, TX
PS10-8: Transcriptional profiling of tumor biopsies in neoadjuvant FourLight-2, a randomized phase 2 window-of-opportunity study, evaluating atirmociclib plus letrozole versus letrozole alone in HR+/HER2− breast cancer
Shom Goel, Peter MacCallum Cancer Centre, Melbourne Victoria, Australia
PS10-9: Znf703 within the 8p11-12 amplicon drives antiestrogen and cdk4/6 inhibitor resistance in estrogen receptor positive breast cancer
Doohyung Lee, UT Southwestern Medical Center, Dallas, TX
PS10-10: Culmerciclib plus fulvestrant versus placebo plus fulvestrant as first-line treatment for patients with HR+/HER2- advanced breast cancer: prespecified final analysis of the phase 3 CULMINATE-2 trial
Erwei Song, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
PS10-11: Palazestrant (OP-1250) in combination with atirmociclib, a phase 1b study, in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+, HER2-) advanced or metastatic breast cancer
Nancy U. Lin, Dana Farber Cancer Institute, Boston, MA
PS10-12: Beyond CDK4/6: New Resistance Mechanisms and Emerging CDK4 and CDK2 Inhibitors
Anton Safonov, Memorial Sloan Kettering Cancer Center, New York, NY

Poster Spotlight 11: Early Onset Breast Cancer 

Moderator: Ann H Partridge, Dana-Farber Cancer Institute, Boston, MA
PS11-1: The most difficult thing for me was learning how to be a survivor: Reflections on a decade of survivorship from a large cohort of young breast cancer patients and survivors
Ann H Partridge, Dana-Farber Cancer Institute, Boston, MA
PS11-2: Somatic genomic profiles and outcomes in young patients with metastatic breast cancer
Erika Belmont, Washington University in St. Louis, Saint Louis, MO
PS11-3: Defining age based thresholds for early onset breast cancer
Sara Myers, The Ohio State University, Columbus, OH
PS11-4: Clinicogenomic Factors Associated with Distant Recurrence in Young-Onset Breast Cancer: A Comprehensive Real-World Analysis
Shifa Kanjwal, UTSW, Dallas, TX
PS11-5: Young Age-associated breast cancer: new color or a different shade of pink
Melissa A Troester, University of North Carolina at Chapel Hill, Chapel Hill, NC
PS11-6: Longitudinal Sexual Health and Body Image Outcomes in Young Women with Breast Cancer
Shari Goldfarb, MSKCC, New York City, NY
PS11-7: Menopausal symptoms in young survivors after >10 years from the breast cancer diagnosis: a subanalysis of the Young Women's Breast Cancer Study
Carmine Valenza, Dana-Farber Cancer Institute, Boston, MA
PS11-8: Real World Data of Breast Cancer Survivors presenting for Perimenopause and Menopause Care
Mindy Goldman, Midi Health, Inc., Palo Alto, CA
PS11-9: Use of assisted reproductive technologyfollowing endocrine therapy among women with hormonereceptorpositivebreast cancer: A population-based analysis of 13 states
Isabel Beshar, University of Texas – MD Anderson Cancer Center, Houston, TX
PS11-10: Addressing fertility concern and emotional well-being from the point of diagnosis: unmet needs of young women with breast cancer — a 12-center study
Hohyun Ryu, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of

Poster Spotlight 12: GLP-1

Moderator: Arun Banu, The University of Texas MD Anderson, Houston, TX
PS12-1: GLP-1 Receptor Agonists and Overall Survival in Breast Cancer: A Systematic Review and Meta-Analysis
Kesar Prajapati, Metropolitan Hospital Center, New York, NY
PS12-2: GLP-1 Targeting Agents Impair Chemoimmunotherapy Response in Triple-Negative Breast Cancer through Tumor-Intrinsic and Microenvironment Mechanisms
Bethania Santos, University of Texas Southwestern Medical Center, Dallas, TX
PS12-3: GLP-1 Receptor Agonist Exposure and Clinical Outcomes in Triple-Negative Breast Cancer Treated with Pembrolizumab-Based Neoadjuvant Therapy: A Propensity Score-Matched Analysis
Grace Gorecki, Allegheny Health Network, Pittsburgh, PA
PS12-4: Fasting-mimicking diet plus neoadjuvant chemotherapy in early TNBC: 5-year survival outcomes and transcriptomic predictors of relapse from the BREAKFAST trial
Francesca Ligorio, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy
PS12-5: Concurrent GLP-1 receptor agonist use and outcomes with capivasertib in metastatic hormone receptor-positive, HER2-negative breast cancer
Zunairah Shah, Roswell park Comprehensive Cancer Center, Buffalo, NY
PS12-6: Impact of GLP-1 on Breast Cancer Care and Outcomes
Sherry Shen, Memorial Sloan Kettering Cancer Center, New York, NY
PS12-7: Glp-1 agonist use and contralateral breast cancer risk
Raissa Kentsa, The University of Texas MD Anderson Cancer Center, Houston, TX
PS12-8: Glucagon-like peptide-1 receptor agonists and incident breast cancer in women: a systematic review and meta-analysis contrasting real-world and randomized evidence.
Angela Theresa Zuffo Yabrude, Universidade Regional de Blumenau, Blumenau, Brazil
PS12-9: Change in Benign Breast Tissue Transcriptomics and other Biomarkers after 6 months of Tirzepatide in Women at High Risk for Development of Breast Cancer
Carol J Fabian, University of Kansas Medical Center, Kansas City, KS
PS12-10: Time-to-event analysis associates GLP-1 use with lower breast cancer incidence and weight loss identifies a lower-risk subgroup
Elizabeth S. McDonald, University of Pennsylvania, Philadelphia, PA
PS12-11: Tirzepatide Improves Metabolic Health and Decreases Mammary Tumor Susceptibility in High-Fat Diet-Fed Wild-Type and Brca1<sup>+/-</sup> Mice
Sailesh Palikhe, University of Kansas Medical Center, Kansas City, KS
PS12-12: Can we prevent breast cancer with GLP-1?
Claudine Isaacs, Georgetown University, Washington, DC

Poster Spotlight 14: Late Breaking Abstracts 

Moderator: Frederick M. Howard, University of Chicago
PS14-1: Prospective-retrospective HeCOG observational trial validation study of a multimodal AI model for 5-year and 10-year distant metastasis risk assessment in early HR+/HER2- breast cancer
Marta Ligero, StratifAI GmbH, Berlin, Germany
PS14-2: Multi-institutional validation of a computational pathology model for late recurrence risk stratification in hormone receptor-positive breast cancer
Satvika Bharadwaj, Georgia Institute of Technology and Emory University, Atlanta, GA
PS14-3: Independent Validation of the AI-Driven Digital Pathology Assay for the 70-Gene Recurrence Signature in the MINDACT Trial
Laura van t Veer, University California San Francisco, San Francisco, CA
PS14-4: Performance of the Sensitivity to Endocrine Therapy (SET<sub>ER/PR</sub>) assay in the ECOG-ACRIN TAILORx trial
Joseph Sparano, Icahn School of Medicine at Mount Sinai, New York, NY
PS14-5: Integration of molecular and pathologic response to neoadjuvant therapy (NAT) could inform risk stratification across response-predictive subtypes in high-risk early-stage breast cancer: Results from >1,200 patients in the I-SPY2 trial
Mark Jesus Magbanua, University of California San Francisco, San Francisco, CA
PS14-6: Ultrasensitive whole genome sequencing tumor informed ctDNA monitoring is highly prognostic and detects molecular recurrence years before clinical relapse in early HR+/HER2- breast cancer
Felicity C Martin, Department of Oncology, University of Cambridge; Precision Breast Cancer Institute, Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge, United Kingdom
PS14-7: Spatial Arrangement of AI-Predicted HER2 Expression from Hematoxylin and Eosin Improves Prediction of Pathologic Complete Response Beyond PAM50 in the NSABP B-41 Trial
Sahar Almahfouz Nasser, Emory University, Atlanta, GA
PS14-8: Blinded external validation of an H&E image-based early distant recurrence (EDR) model for 5-year distant recurrence-free survival in SWOG S1007 (RxPONDER)
Funda Meric-Bernstam, UT MD Anderson Cancer Center, Houston, TX
PS14-9: Independent Validation of the HER2DX CNS Progression Score in the Pertuzumab Arm of the Phase III CLEOPATRA Trial
Rodrigo Sanchez-Bayona, Hospital Universitario 12 de Octubre. Instituto de Investigacion Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain
PS14-10: Elacestrant in combination with capivasertib in patients with ER+/HER2- advanced breast cancer: phase 1b/2 results from ELEVATE, an open-label, umbrella study
Hope Rugo, City of Hope Comprehensive Cancer Center, Duarte, CA

Poster Spotlight 9: This is Not Your Halsted’s Mastectomy: Balancing Innovation and Outcomes

Moderator: E Shelley Hwang, Stanford University, Palo Alto, CA
PS9-1: Comparison of Oncologic and Surgical Outcomes Between Robotic Mastectomy and Conventional Mastectomy Followed by Reconstruction After Neoadjuvant Chemotherapy in Breast Cancer Patients
Joongkwon Lee, Asan Medical Center, Seoul, Korea, Republic of
PS9-2: Impact of skin and nipple-areolar complex preservation on local recurrence after mastectomy: A competing-risk analysis
Eunhye Kang, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea, Republic of
PS9-3: Therapeutic Nipple-Sparing Mastectomy with Immediate Breast Reconstruction: Results of the Multicenter Prospective MAPAM-01 Trial (NCT02311959)
Eva Jouve, University of Toulouse – Claudius Regaud Institute – IUCT Oncopole, TOULOUSE, France
PS9-4: Longitudinal changes in patient-reported outcomes following skin- or nipple-sparing mastectomy and pre-pectoral versus sub-pectoral implant positioning – a secondary endpoint analysis of the OPBC-02/PREPEC trial
Martin Heidinger, University Hospital Basel, Basel, Switzerland
PS9-5: Exploring women’s experiences of seeking and professionals’ perspectives on offering contralateral symmetrising mastectomy as an alternative to breast reconstruction after unilateral mastectomy for breast cancer: A UK Qualitative Interview Study
Eleanor Ferris, Bristol Medical School, Bristol, United Kingdom
PS9-7: Use of adjunct mesh in pre-pectoral implant-based breast reconstruction and surgical risk in the setting of radiotherapy
Martin Heidinger, University Hospital Basel, Basel, Switzerland
PS9-8: Surgical complications by pre- versus subpectoral implant-based breast reconstruction: A preplanned OPBC-02/PREPEC sub-study
Martin Heidinger, University Hospital Basel, Basel, Switzerland
PS9-9: Partbrecon-pro study: PARTial BREast reCONstruction with chest wall perforator flap, a PROspective study of clinical and patient reported outcomes: early results
Amit Agrawal, Cambridge University Hospitals, Cambridge, United Kingdom
PS9-10: Profunda versus Lumbar Artery Perforator Flaps in Autologous Breast Reconstruction: Outcomes in 795 Flaps
Dominic Henn, UT Southwestern, Dallas, TX
PS9-11: Early Postoperative Pain Reduction and Opioid-sparing Effect of Suzetrigine in Autologous Breast Reconstruction
Dominic Henn, UT Southwestern Medical Center, Dallas, TX
PS9-12: Innovating Reconstruction Approaches
Marios Konstantinos Tasoulis, The Royal Marsden Hospital, London, United Kingdom

Precision Medicine for Patients Living with Breast Cancer

Moderator: Carlos L Arteaga, UT Southwestern Medical Center, Dallas, TX
PL3-01: Precision Medicine for Patients Living with Breast Cancer
Fabrice Andre, Institut Gustave Roussy, Villejuif, France

General Session 3

Moderator: Sarat Chandarlapaty, Memorial Sloan Kettering Cancer Center, New York, NY, Shou-Ching Tang, LSU School of Medicine, New Orleans, New Orleans, LA
GS3-1: Final overall survival of imlunestrant versus standard of care in ESR1-mutated advanced breast cancer: updated efficacy from the phase 3 EMBER-3 trial
Komal L Jhaveri, Memorial Sloan Kettering Cancer Center, New York, NY
GS3-2: Camizestrant + palbociclib (palbo) vs anastrozole (ana) + palbo as upfront first-line (1L) therapy in patients (pts) with ER+/HER2- advanced breast cancer (ABC): results from the randomized phase 3 SERENA-4 trial
Fabrice André, Institut Gustave Roussy, Villejuif, France
GS3-3: Discussant for 3305 and 3459
Aditya Bardia, University of California Los Angeles, Los Angeles, CA
GS3-4: Characterization of clinical outcomes in monarchE by histologic, molecular, and genomic subtypes: Updated baseline tumor analysis from patients with HR+, HER2−, node-positive, high-risk early breast cancer
Nick Turner, Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom
GS3-5: Longitudinal analysis of imaging biomarkers and ctDNA to predict neoadjuvant therapy response: a retrospective study from I-SPY 2
Wen Li, University of California, San Francisco, San Francisco, CA
GS3-6: Translational discovery and validation of genomic alterations associated with AKT inhibitor (AKTi) resistance in hormone receptor-positive, HER2-negative metastatic breast cancer (HR+/HER2- MBC)
Maxwell R Lloyd, Massachusetts General Hospital, Boston, MA
GS3-7: Vaccination to target PARP inhibitor resistance caused by BRCA1/2 reversion mutations
Stephen J. Pettitt, Institute of Cancer Research, London, United Kingdom
GS3-8: Efficacy and safety of neoadjuvant trastuzumab deruxtecan (T-DXd) monotherapy versus standard of care (SoC) therapy in stage I-II HER2+ early breast cancer (eBC): First results from WSG ADAPT-HER2-IV
Nadia Harbeck, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, Munich, Germany
GS3-9: Trastuzumab rezetecan with or without pertuzumab in untreated HER2-positive recurrent or metastatic breast cancer: a multicenter, randomized phase 3 study (HORIZON-Breast07)
Yongmei Yin, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
GS3-10: The STOP-HER2 Trial: A Phase 2 Study of Stopping Trastuzumab – Outcomes in Patients (pts) with HER2+ Metastatic Breast Cancer (MBC) (TBCRC 062)
Heather A Parsons, Fred Hutchinson Cancer Center, Seattle, WA

Special Session 10: Breast Cancer Risk Through the Lens of Women’s Health: Screening and Interventions in perspective

Moderator: Laura Esserman, University of California, San Francisco, San Francisco, CA
SS10-1: Introduction to Breast Cancer Risk in Young Women
Laura Esserman, University of California, San Francisco, San Francisco, CA
SS10-3: Weighing the Risks and Benefits of Menopausal Hormone Therapy
Erin McCreary
SS10-2: Breast Cancer Screening Beyond 74: Balancing Risk, Comorbidities, and Prevention
Mara A Schonberg

Poster Session 5

Rapid Fire 7

Moderator: Reshma L Mahtani, Baptist Health Wertheim Cancer Institute, Miami, FL, Joyce O'Shaughnessy
RF7-1: Efficacy and Safety of a 6-Month Pre‑mixed Depot formulation, Leuprorelin Mesylate Injection (6M) with Tamoxifen in Premenopausal HR+ Breast Cancer: A Phase III, Randomized, Open-Label, Non-Inferiority Study in China
Jian Zhang, Fudan University Shanghai Cancer Center, Shanghai, China
RF7-2: I-SPY 2 Endocrine Optimization Pilot (EOP): elagolix vs GnRH agonist as ovarian function suppression (OFS) in premenopausal patients receiving neoadjuvant (Z)-endoxifen for estrogen receptor positive (ER+)/HER2 negative (HER2-) stage 2/3 breast cancer (BC)
Annabelle Duflock, University of California, San Francisco, San Francisco, CA
RF7-3: A randomised non-comparative phase II study of Adjuvant PALbociclib as an Alternative to CHemotherapy in Elderly patientS with high-risk ER+/HER2- early breast cancer (APPALACHES); EORTC-1745-ETF-BCG
Hans Wildiers, university hospitals leuven, leuven, Belgium
RF7-4: Afuresertib and fulvestrant for PIK3CA/AKT1/PTEN-altered, hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from the phase III part of LAE205INT3101 trial
Pin Zhang, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China
RF7-5: Updated Efficacy Results From LEONARDA-2: A Phase III, Randomized, Placebo-Controlled Trial of Lerociclib Plus Letrozole as First-Line Therapy for HR+/HER2- Advanced Breast Cancer
Xichun Hu, Fudan University Cancer Center, Shanghai, China

Debate: Trastuzumab Deruxtecan- Before or After Surgery?

Moderator: William Gradishar, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL
CT3-02: Adjuvant Therapy
Nadia Harbeck, LMU University Hospital, Munich, Germany
CT3-03: Neoadjuvant Therapy
Sibylle Loibl, GBG Forschungs GmbH, Neu-Isenburg, Goethe University of Frankfurt, Frankfurt, Germany

Year in Review

Moderator: Virginia G Kaklamani, UT Health San Antonio, San Antonio, TX
SS6-01: Basic Science Review
Qing Zhang, UT Southwestern Medical Center, Dallas, TX
SS6-02: Translational Science Review
Christos Sotiriou, Institut Jules Bordet, Brussels, Belgium
SS6-03: Early Breast Cancer
Erica L. Mayer, Dana-Farber Cancer Institute, Boston, MA
SS6-04: Advanced Breast Cancer Review
Barbara Pistilli, Gustave Roussy, Villejuif, France

View from the Trenches: What to do on Monday Morning

Moderator: Javier Cortes
Panelist- Medical Oncology
William Gradishar, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL
Panelist- Surgical Oncology
Mediget Teshome
Panelist- Radiation Oncology
Jonathan Strauss, Feinberg School of Medicine, Chicago, IL
Advocate: Ashley Dedmon